Search Results for: Emergency

Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab vs. ipilimumab plus nivolumab in US academic centers.

Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab vs. ipilimumab plus nivolumab in US academic centers.

Melanoma Literature
Publication date: Nov 21, 2019 Background: Both pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are FDA-approved immunotherapy regimens for advanced melanoma (AM). Each regimen has different toxicity profiles potentially impacting health care ... Read more